CSPC Pharmaceutical Group Limited (CHJTF)
USD 0.64
(3.23%)
USD 0.64
(3.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.14 Billion USD | -1.54% |
| 2022 | 1.29 Billion USD | 6.14% |
| 2021 | 1.18 Billion USD | 21.47% |
| 2020 | 1.04 Billion USD | 20.88% |
| 2019 | 5.35 Billion USD | 18.37% |
| 2018 | 632.08 Million USD | 17.37% |
| 2017 | 538.55 Million USD | 33.3% |
| 2016 | 404 Million USD | 16.61% |
| 2015 | 346.44 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 1.94 Billion CNY | 0.0% |
| 2024 Q1 | 2.26 Billion CNY | 26.54% |
| 2023 Q2 | 579.64 Million USD | -67.53% |
| 2023 FY | - USD | -1.54% |
| 2023 Q4 | 1.78 Billion CNY | -7.53% |
| 2023 Q3 | 1.93 Billion CNY | 233.71% |
| 2023 Q1 | 1.78 Billion CNY | 219.73% |
| 2022 Q2 | 277.74 Million CNY | -12.22% |
| 2022 Q4 | 558.4 Million USD | -70.23% |
| 2022 Q3 | 1.87 Billion CNY | 575.34% |
| 2022 Q1 | 316.43 Million CNY | 11.15% |
| 2022 FY | - USD | 6.14% |
| 2021 Q4 | 284.69 Million CNY | 8.15% |
| 2021 Q2 | 250.82 Million CNY | -10.03% |
| 2021 Q3 | 263.23 Million CNY | 4.95% |
| 2021 FY | - USD | 21.47% |
| 2021 Q1 | 278.77 Million CNY | 18.53% |
| 2020 FY | - USD | 20.88% |
| 2020 Q4 | 235.19 Million CNY | -6.44% |
| 2020 Q3 | 251.39 Million CNY | 12.11% |
| 2020 Q2 | 224.24 Million CNY | 23.82% |
| 2020 Q1 | 181.1 Million CNY | 4.15% |
| 2019 Q4 | 173.89 Million CNY | -2.56% |
| 2019 Q3 | 178.46 Million CNY | -4.61% |
| 2019 Q2 | 187.08 Million CNY | -2.13% |
| 2019 FY | - USD | 18.37% |
| 2019 Q1 | 191.15 Million CNY | 32.04% |
| 2018 FY | - USD | 17.37% |
| 2018 Q4 | 144.76 Million CNY | -5.74% |
| 2018 Q1 | 167.6 Million CNY | 22.5% |
| 2018 Q3 | 153.58 Million CNY | -4.9% |
| 2018 Q2 | 161.49 Million CNY | -3.65% |
| 2017 Q2 | 129.65 Million CNY | 6.42% |
| 2017 FY | - USD | 33.3% |
| 2017 Q4 | 136.82 Million CNY | 1.13% |
| 2017 Q3 | 135.29 Million CNY | 4.35% |
| 2017 Q1 | 121.83 Million CNY | 16.46% |
| 2016 Q2 | 104.65 Million CNY | 3.76% |
| 2016 Q3 | 105.92 Million CNY | 1.22% |
| 2016 Q1 | 100.86 Million CNY | 12.04% |
| 2016 Q4 | 104.61 Million CNY | -1.24% |
| 2016 FY | - USD | 16.61% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | 90.02 Million CNY | 0.57% |
| 2015 Q3 | 89.5 Million CNY | -1.35% |
| 2015 Q2 | 90.73 Million CNY | 6.0% |
| 2015 Q1 | 85.59 Million CNY | 12.52% |
| 2014 Q4 | 76.07 Million CNY | 0.61% |
| 2014 Q3 | 75.61 Million CNY | -0.87% |
| 2014 Q1 | 66.76 Million CNY | 7.32% |
| 2014 Q2 | 76.27 Million CNY | 14.25% |
| 2013 Q2 | 56.7 Million CNY | 19.81% |
| 2013 Q3 | 42.89 Million CNY | -24.34% |
| 2013 Q4 | 62.2 Million CNY | 45.0% |
| 2013 Q1 | 47.32 Million CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | 91.361% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | 94.087% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 2991.488% |
| Novartis AG | 19.51 Billion USD | 94.118% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | -298.449% |